Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CTX 213

Next Previous
Drug Profile

CTX 213

Alternative Names: CTX213; Deviceless beta cell replacement - CRISPR Therapeutics

Latest Information Update: 27 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CRISPR Therapeutics
  • Class Gene therapies; Stem cell therapies
  • Mechanism of Action Pancreatic beta cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Research Type 1 diabetes mellitus

Most Recent Events

  • 27 Jun 2025 CTX 213 is available for licensing as of 27 Jun 2025. https://crisprtx.com/about-us/partnerships
  • 16 Apr 2025 CRISPR Therapeutics has patent application pending for CTX 213 in Canada
  • 16 Apr 2025 Early research in Type 1 diabetes mellitus in USA (unspecified route)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top